101 related articles for article (PubMed ID: 2374771)
1. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
Fritze J; Becker T; Ziegler V; Laux G; Riederer P
Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
[TBL] [Abstract][Full Text] [Related]
2. Brofaromine (CGP 11 305 A): estimation of plasma concentrations by a biologic technique as compared to liquid chromatography.
Fritze J; Becker T; Ziegler V; Laux G; Bieck P; Sofic E; Riederer P
J Neural Transm Suppl; 1990; 32():197-201. PubMed ID: 2089091
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
Schiwy W; Heath WR; Delini-Stula A
J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
[TBL] [Abstract][Full Text] [Related]
4. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
Celada P; Pérez J; Alvarez E; Artigas F
J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522
[TBL] [Abstract][Full Text] [Related]
6. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
[TBL] [Abstract][Full Text] [Related]
7. Reversible monoamine oxidase-A inhibitors in resistant major depression.
Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
[TBL] [Abstract][Full Text] [Related]
8. Results of an open clinical trial of brofaromine (CGP 11 305 A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression.
Steiger A; Holsboer F; Gerken A; Demisch L; Benkert O
Pharmacopsychiatry; 1987 Nov; 20(6):262-9. PubMed ID: 3432361
[TBL] [Abstract][Full Text] [Related]
9. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
Volz HP; Heimann H; Bellaire J; Laux G; Möller HJ
Pharmacopsychiatry; 1994 Jul; 27(4):152-8. PubMed ID: 7972347
[TBL] [Abstract][Full Text] [Related]
10. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
Laux G; Classen W; Sofic E; Becker T; Riederer P; Lesch KP; Struck M; Beckmann H
J Neural Transm Suppl; 1990; 32():189-95. PubMed ID: 2089089
[TBL] [Abstract][Full Text] [Related]
11. Reversible monoamine oxidase-A inhibitors in panic disorder.
Bakish D; Saxena BM; Bowen R; D'Souza J
Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor--an open study.
Delcker A; Gaertner HJ
Eur Neuropsychopharmacol; 1991 May; 1(2):177-80. PubMed ID: 1821707
[TBL] [Abstract][Full Text] [Related]
13. MAO inhibition and clinical response in depressed patients treated with phenelzine.
Bresnahan DB; Pandey GN; Janicak PG; Sharma R; Boshes RA; Chang SS; Gierl BL; Davis JM
J Clin Psychiatry; 1990 Feb; 51(2):47-50. PubMed ID: 2298705
[TBL] [Abstract][Full Text] [Related]
14. Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors.
Georgotas A; Friedman E; McCarthy M; Mann J; Krakowski M; Siegel R; Ferris S
Biol Psychiatry; 1983 Feb; 18(2):195-205. PubMed ID: 6830930
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.
Kennedy SH; Goldbloom DS; Ralevski E; Davis C; D'Souza JD; Lofchy J
J Clin Psychopharmacol; 1993 Dec; 13(6):415-22. PubMed ID: 8120155
[TBL] [Abstract][Full Text] [Related]
16. Correlations of plasma and urinary phenylacetic acid and phenylethylamine concentrations with eating behavior and mood rating scores in brofaromine-treated women with bulimia nervosa.
Davis BA; Kennedy SH; D'Souza J; Durden DA; Goldbloom DS; Boulton AA
J Psychiatry Neurosci; 1994 Jul; 19(4):282-8. PubMed ID: 7918350
[TBL] [Abstract][Full Text] [Related]
17. Reversible monoamine oxidase-A inhibitors in social phobia.
Liebowitz MR; Schneier F; Gitow A; Feerick J
Clin Neuropharmacol; 1993; 16 Suppl 2():S83-8. PubMed ID: 8313403
[TBL] [Abstract][Full Text] [Related]
18. Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings.
Möller HJ; Wendt G; Waldmeier P
Pharmacopsychiatry; 1991 Mar; 24(2):50-4. PubMed ID: 1852792
[TBL] [Abstract][Full Text] [Related]
19. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.
Nolen WA; Haffmans PM; Bouvy PF; Duivenvoorden HJ
J Affect Disord; 1993 Jul; 28(3):189-97. PubMed ID: 8408980
[TBL] [Abstract][Full Text] [Related]
20. Brofaromine in elderly major depressed patients--a comparative trial versus imipramine.
Möller HJ; Volz HP
Eur Neuropsychopharmacol; 1993 Dec; 3(4):501-10. PubMed ID: 8111223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
